Myeloma Treatment at the University of Colorado Cancer Center
UCCC is the region's only NCI-designated Comprehensive Cancer Center
Call us at (720) 848-0300 or submit an online form.
A diagnosis of myeloma can be overwhelming. But there is hope.
Myeloma treatment and therapies have greatly improved in the last 20 years. A well-coordinated and customized sequence of chemotherapy and stem cell transplantation has greatly extended the lives of most patients with multiple myeloma.
A pioneer in advanced treatment
The University of Colorado Cancer Center has been a pioneer in these advances. Beyond our cutting-edge successes in the fight against cancer, you’ll find a caring team of experts you can trust. And the same expert team of doctors, nurses and specialists walk alongside you throughout your entire journey.
Our dedication to a cure for cancer is unwavering. That’s why our 5-year survival rates are up to 30% higher than state, regional and national averages.
To begin your journey with a committed and caring team of myeloma experts, call us today at (720) 848-0300.
For consultations and referrals, please call Tina Russell, our outpatient coordinator, at (720) 848-0372.
A partial list of our current myeloma clinical trials:
- A study of induction therapy with 'bortezomib + lenalidomide + dexamethasone + doxorubicin (VLDA)' for patients with multiple myeloma: UCHSC 08-0814
- A study of infusional melphalan + bortezomib for myeloablative therapy prior to autologous transplant for patients with multiple myeloma: UCHSC 08-0817
- A study for therapy with 'bortezomib + lenalidomide + dexamethasone' with 'lenalidomide + dexamethasone' as post-transplant consolidation and maintenance for patients with symptomatic multiple myeloma following autologous transplantation: UCHSC 08-0816
To find out more about clinical trials, contact Colleen Kellackey at (720) 848-1246 or Colleen.Kellackey@ucdenver.edu
Myeloma and Amyloidosis at a Glance
Myeloma is a type of cancer in the plasma cells, which are immune system cells in the bone marrow. Some people have no symptoms, but others may have problems such as anemia, elevated blood calcium, kidney damage, bone disease, amyloidosis or frequent infections.
Amyloidosis is the name for a group of diseases in which organ systems in the body accumulate deposits of abnormal proteins known as amyloid. Although amyloidosis is not cancer, it is a blood disorder that can be disabling or life-threatening. Most commonly, it affects the kidney, heart, liver and autonomic or peripheral nerves.
- There are 69,598 people living with or in remission from myeloma in the U.S.
- Approximately 20,180 people are diagnosed with myeloma in the United States each year.
- The median age at diagnosis is 70 years; myeloma rarely occurs in people under age 45.
- From 1975 to 2007, the incidence of myeloma increased by 11.4 percent.
- The incidence of myeloma among African Americans was almost 105 percent greater than myeloma incidence among Caucasians in 2007.
- About 1,200 to 3,200 new amyloidosis cases are diagnosed nationwide each year.
Source: The Leukemia and Lymphoma Society